ZYL 3177X

Drug Profile

ZYL 3177X

Alternative Names: ZYL3177X

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zylera Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Unspecified

Most Recent Events

  • 17 Nov 2017 Zylera Pharmaceuticals was acquired by Cerecor as result of the acquisition of TRx pharma
  • 28 Dec 2015 Phase-II clinical trials in Undefined indication in USA (unspecified route)
  • 26 Apr 2012 ZYL 3177X is available for licensing as of 26 Apr 2012. http://www.zylera.com/research-and-development/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top